Infliximab Therapy for Individuals with Crohn's Disease: Analysis of Health Care Utilization and Expenditures
Research Projects – Health
The Society of Actuaries' Health Section is pleased to make available a research report comparing health care utilization and expenditures for individuals with Crohn's disease. Employing two methodological approaches, the report assesses the impact of infliximab therapy on direct health care utilization and expenditures when used by privately insured individuals with Crohn's.
The report was authored by Patrick Meek, Nilay Shah, Holly Van Houten, Bora Gumustop, and Marjorie Rosenberg.
The SOA would like to thank the following individuals for help in initiating the project that led to the report:
- Margaret Wear
- John Bertko
- Kevin Dolsky
- Gregory Durant
- John Governale
- Toby Hall
- Thomas Tomczyk
Report Disclaimer: The opinions expressed and conclusions reached by the authors are their own and do not represent any official position or opinion of the Society of Actuaries or its members. The Society of Actuaries makes no warranty, guarantee, or representation, expressed or implied, as to the accuracy of the information.
If you have any questions or comments regarding the report, please contact Steve Siegel, Research Actuary.